Dementia / Alzheimer's Prevention - Part 1
- Dr. Thomas J. Lewis
- 2 hours ago
- 4 min read
Here is a link to the video on this topic.
The meeting focused on Dr. Lewis' presentation on dementia prevention and early detection, in which he discussed how lifestyle factors and underlying infections contribute to neurodegenerative diseases.
Dr. Lewis explained that early detection through cognitive testing and eye exams is crucial, as brain atrophy can begin years before clinical symptoms appear. He emphasized that while there's no true prevention, catching dementia early enough to address underlying causes like inflammation and infection is key. The presentation covered how beta-amyloid acts as an antimicrobial peptide and how tau hyperphosphorylation serves as a protective mechanism in response to hypoxia. Dr. Lewis recommended basic testing, including cognitive assessments, blood work, and eye exams, while noting that conventional medical treatments often overlook the root causes of dementia.
AI Summary
Neurodegenerative Disease Detection and Research
Dr. Thomas discussed the similarities between different neurodegenerative diseases, emphasizing that while they affect different parts of the brain, the underlying processes are often similar. He highlighted the importance of early detection, using glaucoma as an example of an early warning sign for Alzheimer's. Dr. Thomas explained that dementia is best understood as a syndrome rather than a single disease, and he emphasized the interconnectedness of various health conditions. He also introduced the concept of hallmarks in neurodegenerative diseases, such as beta amyloid, and discussed the potential of using peptides to treat inflammation and support immunity. Dr. Carter corrected Dr. Thomas, noting that beta amyloid is an antimicrobial peptide. The discussion concluded with a focus on the use of optical coherence tomography (OCT) to detect neurodegenerative changes in the eye, which can be an early indicator of brain changes.
Neurodegenerative Disease Misconceptions Discussion
Dr. Thomas discussed the misconceptions around neurodegenerative diseases, emphasizing that they are not infectious in the traditional sense but can be triggered or accelerated by viral and bacterial infections. He challenged the notion that these diseases are primarily genetic, citing evidence that suggests lifestyle factors, such as physical activity and diet, play a significant role in their prevalence. Dr. Thomas also highlighted the importance of early detection and maintaining a healthy lifestyle to prevent or delay the onset of neurodegenerative diseases.
Neurological Links to Dementia Risk
Dr. Thomas discussed the link between neurological issues, depression, and anxiety to increased risk of Alzheimer's and dementia, citing a Danish cohort study showing a 2.5 times higher hazard ratio for dementia in people with depression. He emphasized the importance of early cognitive monitoring, particularly for those over 40, and highlighted that conditions like depression and anxiety are associated with an increased risk of dementia. Dr. Thomas also mentioned a study showing up to 15% atrophy in the hippocampus before cognitive impairment diagnosis, advocating for more effective screening methods beyond the limited mini-mental state exam.
Cognitive Function Testing Discussion
Dr. Thomas and Michael Carter discussed cognitive function tests, focusing on the CNS Vital Signs test, which Dr. Thomas recommended for assessing cognitive impairment. They criticized the standard psychiatric approach to cognitive issues, highlighting limitations in current treatments and diagnostic tools. Dr. Thomas expressed concerns about the overuse of SSRIs and monoclonal antibodies in treating cognitive disorders, emphasizing the need for better diagnostic methods and treatments.
Brain Function Diagnostic Tools Discussion
The group discussed various diagnostic tools for brain function assessment, with Dr. Thomas expressing a preference for quantitative EEG over functional images, while Dr. Harvey emphasized the importance of the QEEG program used and shared his experience with the Bender Gestalt test, which he found valuable despite his initial skepticism. They also reviewed laboratory tests for dementia, noting that while these tests can identify hallmarks like amyloid beta and tau, none directly address the root cause of neurodegeneration, leading Dr. Thomas to question the current recommendation against routine MCI diagnosis due to potential overdiagnosis, when underdiagnosis may be a greater issue.
Alzheimer's Research and Detection Methods
Dr. Thomas discussed the potential role of beta-amyloid 142 as an antimicrobial peptide, referencing research by Robert Moyer and Rudolf Tanzi at Harvard. He highlighted the work of Judith McClosie, who demonstrated a causal link between ketosis and Alzheimer's disease, and mentioned the involvement of various researchers in studying the connection between bacterial infections and Alzheimer's. Dr. Thomas also touched on the controversy surrounding the approval of a drug for Alzheimer's and the possibility of using eye exams as an early detection method for the disease.
Eye-Brain Condition Correlation Research
Dr. Thomas discussed the correlation between eye and brain conditions, particularly supranuclear cortical cataracts and Alzheimer's plaques, and highlighted the potential of using a slit-lamp microscope for early diagnosis, despite the lack of reimbursement codes for more advanced instruments like the MP-1. He emphasized the challenges of fighting medical dogma and the need for further studies to establish causation, mentioning his research on hyperphosphorylated tau in hibernating animals and its potential link to local hypoxia and energy conservation in the brain.
Hypoxia and Tau in Dementia
Dr. Thomas discussed the relationship between hypoxia and tau hyperphosphorylation in the brain, explaining that while this mechanism provides protection in hibernating animals, it may contribute to dementia in humans due to reduced local oxygen levels despite normal blood oxygen saturation. He criticized current Alzheimer's therapies that target tau hyperphosphorylation, noting that TauRx's failure in clinical trials was predictable given this understanding. Dr. Thomas emphasized the importance of early testing for dementia through basic measures like eye exams, blood tests, and CNS vital signs, and suggested that lifestyle factors such as reduced micronutrient intake and increased inflammation contribute significantly to dementia risk.
Be bold and brave. Fight the dogmas!
Comments